Personalized approach for direct oral anticoagulant prescription: from theory to practice
- 作者: Skripka A1, Kogay V1, Listratov A1, Sokolova A1, Napalkov D1, Fomin V1
-
隶属关系:
- Sechenov First Moscow State Medical University (Sechenov University)
- 期: 卷 91, 编号 7 (2019)
- 页面: 111-120
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33649
- DOI: https://doi.org/10.26442/00403660.2019.07.000045
- ID: 33649
如何引用文章
全文:
详细
作者简介
A Skripka
Sechenov First Moscow State Medical University (Sechenov University)аспирант каф. факультетской терапии №1 Института клинической медицины ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет) Moscow, Russia
V Kogay
Sechenov First Moscow State Medical University (Sechenov University)студентка VI курса Международной школы «Медицина будущего» научно-технологического парка биомедицины ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет) Moscow, Russia
A Listratov
Sechenov First Moscow State Medical University (Sechenov University)студент VI курса Международной школы «Медицина будущего» научно-технологического парка биомедицины ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет) Moscow, Russia
A Sokolova
Sechenov First Moscow State Medical University (Sechenov University)к.м.н., ассистент каф. факультетской терапии № 1 Института клинической медицины ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет) Moscow, Russia
D Napalkov
Sechenov First Moscow State Medical University (Sechenov University)
Email: dminap@mail.ru
д.м.н., проф. каф. факультетской терапии № 1 Института клинической медицины ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет) Moscow, Russia
V Fomin
Sechenov First Moscow State Medical University (Sechenov University)д.м.н., проф., член-корр. РАН, зав. каф. факультетской терапии №1 Института клинической медицины ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет) Moscow, Russia
参考
- Сычев Д.А., Игнатьев И.В., Емельянов Н.В., Савельева М.И., Дмитриев В.А., Кукес В.Г., Герасимова К.В. Фармакогенетическое тестирование: первые шаги в реальной клинической практике и проблемы стандартизации. Проблемы стандартизации в здравоохранении. 2009;1:43-55.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H.C, Heidbuchel H, Hendriks J, Hindricks G, Manolis A.S, Oldgren J, Popescu B.A, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro J.M, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser S.H, Kolh P, Lip G.Y, Manolis A, Mc Murray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo J.L, Taylor C.J, Van Gelder I.C, Voors A.A, Windecker S, Zamorano J.L, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):2893-962. doi: 10.1093/europace/euw295
- Инструкция по применению лекарственного препарата Прадакса. Государственный реестр лекарственных средств. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e4817690-bf14-4e4e-9562-256d415636c7&t=. Ссылка активна на 25.10.2018.
- Reilly P.A, Lehr T, Haertter S, Connolly S.J, Yusuf S, Eikelboom J.W, Ezekowitz M.D, Nehmiz G, Wang S, Wallentin L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104
- Ezekowitz M.D, Connolly S, Parekh A, Reilly P.A, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long - term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805-10.e1-2. doi: 10.1016/j.ahj.2009.02.005
- Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz M.D, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen A.C, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIR CULATIONAHA.112.001233
- Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, Carraro P, Salomone L, Paniccia R, Paoletti O, Poli D, Palareti G. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thromb Res. 2016 Jan;137:178-83. doi: 10.1016/j.thromres.2015.12.001
- Pharm GKB. Available at: https://www.pharmgkb.org/chemical/PA1651 10351/clinicalAnnotation. Accessed October 24, 2018.
- Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol Drug Interact. 2014;29(3):143-51. doi: 10.1515/dmdi-2014-0009
- Dimatteo C, D'Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia G.L, Buono M, Grandone E, Testa S, Margaglione M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016 Aug; 144:1-5. doi: 10.1016/j.thromres.2016.05.025
- Мещеряков Ю.В., Чертовских Я.В., Сычёв Д.А. Фармакогенетика нового орального антикоагулянта дабигатрана - роль полиморфизма rs2244613 CES1 в развитии нежелательных побочных реакций. Фармакогенетика и фармакогеномика. 2017;2:18-9.
- Сычев Д.А., Казаков Р.Е., Отделенов В.А., Прокофьев А.Б. Прикладные аспекты применения фармакогенетического тестирования для персонализации применения пероральных антикоагулянтов в российских условиях. Рациональная фармакотерапия в кардиологии. 2013;9(5):525-31. doi: 10.20996/1819-6446-2013-9-5-525-531
- Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2011;26(1):27-32. doi: 10.1111/j.1472-8206. 2011.00981.x
- Kubitza D, Becka M, Roth A, Mueck W. The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor. J Clin Pharmacol. 2013;53(3):249-55. doi: 10.1002/jcph.5
- Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects. J Clini Pharmacol. 2007;47(2):218-26. doi: 10.1177/009127000626058
- Инструкция по применению лекарственного препарата Ксарелто. Государственный реестр лекарственных средств. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=732bced6-0374-4deb-a882-c6745d527c8d&t=. Ссылка активна на 24.10.2018.
- Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89-98. doi: 10.1111/bcp.12054
- Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) an oral, direct Factor Xa inhibitor has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63(4):469-76. doi: 10.1111/j.1365-2125.2006.02776.x
- Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin. J Clin Pharmacol. 2006;46(9):981-90. doi: 10.1177/0091270006292127
- Kubitza D, Becka M, Mück W, Schwers S. Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study. Pharmaceuticals. 2012;5(3):279-96. doi: 10.3390/ph5030279
- Kubitza D, Becka M, Schwers S, Voith B. Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. Clin Pharmacol Drug Dev. 2013;2(3):270-7. doi: 10.1002/cpdd.26
- Kubitza D, Becka M, Mück W, Krätzschmar J. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol. 2014;78(2):353-63. doi: 10.1111/bcp.12349
- Kubitza D, Becka M, Roth A, Mueck W. Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects. J International Med Research. 2012;40(5):1688-707. doi: 10.1177/03000 6051204000508
- Mueck W, Kubitza D, Becka M. Co - administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. doi: 10.1111/ bcp.12075
- Maier C, Duncan A, Hill C. Pharmacogenetics in Oral Antithrombotic Therapy. Clin Lab Med. 2016;36(3):461-72. doi: 10.1016/j.cll.2016.05. 002
- Sychev D.A, Vardanyan A, Rozhkov A, Hachatryan E, Badanyan A, Smirnov V, Ananichuk A, Denisenko N. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-4. doi: 10.1089/gtmb.2017.0152
- Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem J.E, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot M.A. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thrombosis and Haemostasis. 2017;15(2):273-83. doi: 10.1111/jth.1357
- Крюков А.В., Сычев Д.А., Терещенко О.В. Фармакогенетические аспекты применения новых оральных антикоагулянтов. Рациональная фармакотерапия в кардиологии. 2017;13(3):416-21. doi: 10.20996/1819-6446-2017-13-3-416-421
- Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol. 2016;7. doi: 10.3389/fphar.2016.00494
- Dideriksen D, Damkier P, Nybo M. Rivaroxaban non - responders: do plasma measurements have a place? Clinical Chemistry and Laboratory Medicine (CCLM). 2017;56(1). doi: 10.1515/cclm-2017-0473
- Ameyaw M.M, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan G.O, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans D.A, Mc Leod H.L. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11(3):217-21. doi: 10.1097/00008571-2001040 00-00005
- Инструкция по применению лекарственного препарата Леветирацетам. Государственный реестр лекарственных средств. Доступно по https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routing Guid= 7277294a-54eb-4b9f-9ebd-9bed37cccfee&t= Ссылка активна на 24.10.2018.
- Stöllberger C, Finsterer J. Interactions between non - vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98-101. doi: 10.1016/j.eplepsyres.2016.06.003
- Gnoth M, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban. J Pharmacology and Experimental Therapeutics. 2011;338(1):372-80. doi: 10.1124/jpet.111.180240
- Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll R.G, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker S.D. Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. JNCI: J National Cancer Institute. 2006;98(23):1739-42. doi: 10.1093/jnci/ djj469
- Gong I, Mansell S, Kim R. Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry. Basic Clin Pharmacol Toxicol. 2012;112(3):164-70. doi: 10.1111/bcpt.12005
- Sim S, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer - reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4(4):278. doi: 10.1186/1479-7364-4-4-278
- O’Connor C, Kiernan T, Yan B. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017;13(7):725-39. doi: 10.1080/17425255.2017.1338274
- Инструкция по применению лекарственного препарата Эликвис. Государственный реестр лекарственных средств. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b0cb1df0-3494-4405-88fd-78b9995872fd&t= Ссылка активна на 24.10.2018.
- Granger C.B, Alexander J.H, Mc Murray J.J, Lopes R.D, Hylek E.M, Hanna M, Al-Khalidi H.R, Ansell J, Atar D, Avezum A, Bahit M.C, Diaz R, Easton J.D, Ezekowitz J.A, Flaker G, Garcia D, Geraldes M, Gersh B.J, Golitsyn S, Goto S, Hermosillo A.G, Hohnloser S.H, Horowitz J, Mohan P, Jansky P, Lewis B.S, Lopez-Sendon J.L, Pais P, Parkhomenko A, Verheugt F.W, Zhu J, Wallentin L. ARISTOTLE Committees and Investigators. Committees and Investigators: apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011 Sep;365:981-92. doi: 10.1056/NEJMoa1107039
- Connolly S.J, Eikelboom J, Joyner C, Diener H.C, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser S.H, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan R.S, Sim K.H, Lewis B.S, Van Mieghem W, Lip G.Y, Kim J.H, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans A.L, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2011;364:806-17. doi: 10.1056/NEJMoa1007432
- Frost C.E, Song Y, Shenker A, Wang J, Barrett Y.C, Schuster A, Harris S.I, La Creta F. Effects of age and sex on the single - dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015 Jun;54(6):651-62. doi: 10.1007/s40262-014-0228-0
- Chang M, Yu Z, Shenker A. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016 May;56(5):637-45. doi: 10.1002/jcph.633
- Mavrakanas T.A, Samer C.F, Nessim S.J. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. J Am Soc Nephrol. 2017 Jul;28(7):2241-8. doi: 10.1681/ASN.2016090980
- Di Minno A, Frigerio B, Spadarella G. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 2017 Jul;31(4):193-203. doi: 10.1016/j.blre.2017.02.001
- Kryukov A.V, Sychev D.A, Andreev D.A, Ryabova A.V, Denisenko N.P, Loskutnikov M.A, Vinogradov O.I, Domashenko M.A. The pharmacokinetics of apixaban in patients with cardioembolic stroke in acute phase. Ration Pharmacother Cardiol. 2016;12(3):253-9. doi: 10.20996/1819-6446-2016-12-3-253-259
- Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost C.E, Maxwell B.D, Chen S.Y, He K, Goosen T.C, Humphreys W.G, Grossman S.J. In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies. Drug Metab Dispos. 2010;38:448-58. doi: 10.1124/dmd.109. 029694
- Kryukov A.V, Sychev D.A, Andreev D.A, Ryzhikova K.A, Grishina E.A, Ryabova A.V, Loskutnikov M.A, Smirnov V.V, Konova O.D, Matsneva I.A, Bochkov P.O. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018 Mar 22;11:43-9. doi: 10.2147/ PGPM.S157111
- Zhang D, He K, Herbst J.J, Kolb J, Shou W, Wang L, Balimane P.V, Han Y.H, Gan J, Frost C.E, Humphreys W.G. Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. Drug Metab Dispos. 2013 Apr;41:827-35. doi: 10.1124/dmd.112.050260
- Dimatteo C, D'Andrea G, Vecchione G. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016 Sep;145:24-6. doi: 10.1016/j.thromres.2016.07.005
- Ueshima S, Hirab D, Fujii R. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017 Sep;27(9):329-36. doi: 10.1097/FPC.0000000000000294
- Weitz J.I, Connolly S.J, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Randomised, parallel - group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-41. doi: 10.1160/TH10-01-0066
- Giugliano R.P, Ruff C.T, Braunwald E, Murphy S.A, Wiviott S.D, Halperin J.L, Waldo A.L, Ezekowitz M.D, Weitz J.I, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip L.T, Patel S.P, Patel I, Hanyok J.J, Mercuri M, Antman E.M; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369:2093-104. doi: 10.1056/NEJMoa1310907
- Mendell J, Johnson L, Chen S. An open - label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015 Dec;55(12):1395-405. doi: 10.1002/jcph.550
- Parasrampuria D.A, Truitt K.E. Pharmacokinetics and pharmacodynamics of edoxaban, a non - vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016 Jun;55(6):641-55. doi: 10.1007/s40262-015-0342-7
- Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circ J. 2015;79(7):1486-95. doi: 10.1253/circj.CJ-14-0942
- Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M. Drug - drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013 Oct;13(5):331-42. doi: 10.1007/s40256-013-0029-0
- Mega J.L, Walker J.R, Ruff C.T, Vandell A.G, Nordio F, Deenadayalu N, Murphy S.A, Lee J, Mercuri M.F, Giugliano R.P, Antman E.M, Braunwald E, Sabatine M.S. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double - blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 6;385(9984):2280-7. doi: 10.1016/S0140-6736(14)61994-2
- Vandell A.G, Walker J, Brown K.S, Zhang G, Lin M, Grosso M.A, Mercuri M.F. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017 Nov;103(22):1800-5. doi: 10.1136/heartjnl-2016-310901
- Vandell A.G, Lee J, Shi M, Rubets I, Brown K.S, Walker J.R. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. Pharmacogenomics J. 2018 Jan;18(1):153-9. doi: 10.1038/tpj.2016.82
- Savaysa (edoxaban) tablets [prescribing information]. Parisippany, NJ: Daiichi Sankyo, Inc; 2015. Available at: https://savaysahcp.com/nvaf-safety-and-efficacy. Accessed October 24, 2018.
- Сайт для расчета дозировки варфарина [Электронный ресурс] Доступно по: http://warfarindosing.org/Source/Home.aspx. Ссылка активна на 10.06.2019.